Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Phase I study of sorafenib in combination with uracil-tegafur in patients with unresectable advanced hepatocellular carcinoma in Japan

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

Shinji Itoh

Citation

Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523

Authors

S. Itoh, K. Shirabe, K. Kimura, H. Okabe, N. Harimoto, T. Ikegami, H. Uchiyama, T. Yoshizumi, T. Ikeda, Y. Maehara

Author affiliations

  • Department Of Surgery And Science, Graduate School Of Medical Sciences, Kyushu University, 812-8582 - Fukuoka/JP
More

Resources

Aim/Background

Our goal was to evaluate the frequency of dose-limiting toxicity and determine the recommended dose of sorafenib administered in combination with uracil-tegafur (UFT) to patients with unresectable advanced hepatocellular carcinoma (HCC).Our goal was to evaluate the frequency of dose-limiting toxicity and determine the recommended dose of sorafenib administered in combination with uracil-tegafur (UFT) to patients with unresectable advanced hepatocellular carcinoma (HCC).

Methods

Patients with unresectable advanced HCC were treated with sorafenib plus UFT by 3 + 3 design. Dose levels were as follows: level 1, 200 mg sorafenib twice daily (400 mg/day) and 100 mg UFT 3 times daily (300 mg/day); level 2, 400 mg sorafenib twice daily (800 mg/day) and 100 mg UFT three times daily (300 mg/day); and level 3, 400 mg sorafenib (800 mg/day) and 200 mg UFT twice daily (400 mg/day). A cycle was 28 days in duration and there were 3 cycles in total.

Results

Eleven patients with unresectable advanced HCC were enrolled in our study. Median patient age was 69 years (range, 56–82). Eight (73%) patients had hepatitis C viral infection. Dose-limiting toxicities including grade 3 erythema multiforme (skin rash) and dehydration occurred at dose level 2. Therefore, the maximum tolerated dose of sorafenib was 400 mg/day (level 1). The most common grade 3 or 4 drug-related adverse reactions included neutropenia (9%), increased levels of lipase (9%), decreased levels of phosphate (9%), fatigue (9%), dehydration (9%), hypertension (9%), skin rash (9%), and hand-foot skin reaction (9%).

Conclusions

The recommended dose of sorafenib in combination with UFT (300 mg/day) was determined to be 200 mg twice daily (400 mg/day) for patients with unresectable advanced HCC.

Clinical trial identification

Disclosure

Y. Maehara: partly supported by research funding from Bayer Yakuhin, Ltd. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings